Tuesday 21 May 2019 ,
Tuesday 21 May 2019 ,
Latest News
  • Tunisia boat capsize: 15 survivors return home
  • NZ mosque attacker charged with terrorism
  • US delays Huawei ban for 90 days
  • Ramadan, Iftar evoke feelings of nostalgia among Rohingyas
  • OC withdrawn over Rajshahi schoolgirl’s suicide after rape
13 May, 2019 00:00 00 AM

FDA approves Eticovo (etanercept-ykro), a Biosimilar to Enbrel

drugs.com
FDA approves Eticovo (etanercept-ykro), a Biosimilar to Enbrel

Samsung Bioepis Co., Ltd. recently announced that the US Food and Drug Administration (FDA) has approved Eticovo (etanercept-ykro), a biosimilar referencing Enbrel (etanercept), across all eligible indications for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis and polyarticular juvenile idiopathic arthritis. Eticovo is Samsung Bioepis’ second anti-TNF biosimilar approved for marketing in the United States (US).

“The approval of Eticovo adds to our growing portfolio of anti-TNF medicines in the US, where we believe biosimilars can bring meaningful value to the country’s healthcare system,” said Christopher Hansung Ko, President & CEO of Samsung Bioepis. “Through relentless process innovation and an uncompromising commitment to quality, we remain dedicated to advancing one of the industry's strongest biosimilar pipelines."

In a 52-week Phase III clinical study, which randomized 596 patients with rheumatoid arthritis across 70 sites in 10 countries, Eticovo demonstrated comparable safety and efficacy to the etanercept reference product (Enbrel®), as evidenced in ACR20 response rate of 80.8% in the Eticovo arm versus 81.5% in the Enbrel® arm ii. This confirmed the 24-week study results of 78.1% in the Eticovo arm versus 80.3% in the Enbrel® arm iii.

About Eticovo (etanercept-ykro)

Eticovo is a tumor necrosis factor (TNF) blocker approved in the US for the following indications:

Rheumatoid Arthritis - Eticovo is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA). Eticovo can be initiated in combination with methotrexate (MTX) or used alone.

Polyarticular Juvenile Idiopathic Arthritis - Eticovo is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older.

Psoriatic Arthritis - Eticovo is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (PsA). Eticovo can be used with or without methotrexate.

Ankylosing Spondylitis - Eticovo is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (AS).

Plaque Psoriasis - Eticovo is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.

Warning: Serious Infections and Malignancies

Serious Infections

Patients treated with etanercept products are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1) and Adverse Reactions (6)]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Eticovo should be discontinued if a patient develops a serious infection or sepsis.

Reported infections include:

Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent tuberculosis before Eticovo use and during therapy. Treatment for latent infection should be initiated prior to Eticovo use.

Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.

Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.

The risks and benefits of treatment with Eticovo should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.

Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with Eticovo, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.

Malignancies

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including etanercept products.

These are not all of the risks associated with Eticovo. The Eticovo Prescribing Information carries warnings regarding serious infections, neurologic reactions, malignancies, patients with heart failure, hematologic reactions, Hepatitis B reactivation, allergic reactions, immunizations, autoimmunity, immunosuppression, use in Wegener’s Granulomatosis patients, use with Anakinra or Abatacept and use in patients with moderate to severe alcoholic hepatitis.

Comments

Most Viewed
Digital Edition
More story
From the Editor

From the Editor

Irritable Bowel Syndrome or IBS is a disorder characterised most commonly by cramping, abdominal pain, bloating, constipation and diarrhea. IBS causes…
FAQ on Irritable Bowel Syndrome

FAQ on Irritable Bowel Syndrome

IBS affects between 25 and 45 million Americans. Most of them are women. People are most likely to get the condition in their late teens to early 40s.…
Irritable bowel syndrome (IBS): a long-term gastrointestinal disorder

Irritable bowel syndrome (IBS): a long-term gastrointestinal disorder

CHRISTIAN NORDQVIST Irritable bowel syndrome, or irritable bowel disease, is a long-term gastrointestinal disorder. It causes abdominal pain, bloating,…
Coping with IBS

Coping with IBS

Coping with irritable bowel syndrome (IBS) presents a number of daily challenges. While there is no cure for the disorder, treatments are available. Learn…
12 Foods to avoid with IBS

12 Foods to avoid with IBS

A healthy diet generally consists of eating a wide variety of nutritious foods in moderation. If you have irritable bowel syndrome (IBS), you may notice…
Bowel movement disorders

Bowel movement disorders

Bowel (intestinal) function varies greatly not only from one person to another but also for any one person at different times. It can be affected by diet,…
Type 2 diabetes: losing even a small amount of weight may lower heart disease risk

Type 2 diabetes: losing even a small amount of weight may lower heart disease risk

People with type 2 diabetes are often encouraged to lose weight. And recent studies have shown that losing a lot of weight can reverse diabetes, meaning…
Autism estimates for the USA are wildly inaccurate, say experts at INSAR 2019

Autism estimates for the USA are wildly inaccurate, say experts at INSAR 2019

SALLY ROBERTSON The Centers for Disease Control and Prevention (CDC) has released new statistics on autism. They estimate that there has been a 15% increase…
Biochemical compound responsible for blood pressure drop in sepsis

Biochemical compound responsible for blood pressure drop in sepsis

MARIA FERNANDA ZIEGLER International research group demonstrates the involvement of singlet molecular oxygen in vasodilation, causing a sharp decline…
icddr,b launches artificial intelligence based  diabetic retinopathy detection

icddr,b launches artificial intelligence based diabetic retinopathy detection

Recently, icddr,b in collaboration with Eyes For All PLC, United Arab Emirates and DIAGNOS Inc, Canada have launched an artificial intelligence (AI) based…
Hospitals to test mums-to-be for risky group-B strep

Hospitals to test mums-to-be for risky group-B strep

Screening for a life-threatening bacterial infection affecting newborn babies is to be offered at 80 hospitals in England, Wales and Scotland. About 150,000…
FDA approves Dengvaxia (dengue vaccine) for the prevention of dengue disease in endemic regions

FDA approves Dengvaxia (dengue vaccine) for the prevention of dengue disease in endemic regions

The U.S. Food and Drug Administration announced recently the approval of Dengvaxia, the first vaccine approved for the prevention of dengue disease caused…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting